Abstract Search

ea0029p80 | Adrenal cortex | ICEECE2012

RRM1 Gene expression affects metabolization and activity of mitotane in adrenocortical cancer cell lines.

Germano A. , Rapa I. , De Francia S. , Volante M. , Laino F. , Duregon E. , Berruti A. , Papotti M. , Terzolo M.

Background: Mitotane (o,pDDD) is the reference therapy for adrenocortical carcinoma (ACC) and should undergo metabolization in o,pDDE and o,pDDA to exert its anti-proliferative activity. We have previously shown that there is a link between RRM1 gene expression and o,pDDD activity in an adjuvant setting. Aim of this study was to assess whether RRM1 gene expression is correlated to the bioavailability and cytotoxic activity of o,pDDD and its metabo...

0 shares

ea0026p27 | Adrenal cortex | ECE2011

Do mitotane levels impact on the outcome of patients treated adjuvantly following radical resection of adrenocortical cancer (ACC)?

Ardito A , Al Ghuzian A , Fassnacht M , Daffara F , Leboulleux S , Wortmann S , Zaggia B , De Francia S , Volante Marco , Gonzaga Luigi , Berruti Alfredo , Allolio Bruno , Baudin Eric , Terzolo Massimo

We have demonstrated that adjuvant mitotane prolong recurrence free survival (RFS) in patients with radically resected ACC. Aim of the present study was to correlate mitotane levels with patient outcome in an adjuvant setting in 3 different referral centres in Europe. There were 120 patients (45 W, 75 M, median age 44 years, range 1676) radically resected for ACC who were treated adjuvantly with mitotane from 1996 to 2010. ACC was stage I in 10 cases, II in 73, III in 31...

0 shares

Endocrine Abstracts

RRM1 Gene expression affects metabolization and activity of mitotane in adrenocortical cancer cell lines.

Do mitotane levels impact on the outcome of patients treated adjuvantly following radical resection of adrenocortical cancer (ACC)?

BiosciAbstracts